Chargement en cours...

Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells

Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia in the chronic phase (CML-CP). However, it is unlikely that they can completely “cure” the disease. This might be because some subpopulations of CML-CP cells such as stem and progenitor cells are resistant to...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Flis, Sylwia, Bratek, Ewelina, Chojnacki, Tomasz, Piskorek, Marlena, Skorski, Tomasz
Format: Artigo
Langue:Inglês
Publié: MDPI 2019
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6826736/
https://ncbi.nlm.nih.gov/pubmed/31614827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11101544
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!